A Phase I/II Study in Combination of Resminostat and Sorafenib in Patients With Advanced Hepatocellular Carcinoma Previously Untreated With Systemic Chemotherapy
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Jan 2017
At a glance
- Drugs Resminostat (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Yakult Honsha
- 24 Jan 2017 According to a 4SC media release, results of subgroup analysis were presented at the 2017 Gastrointestinal Cancers Symposium.
- 24 Jan 2017 Results of subgroup analysis, published in a 4SC media release.
- 21 Jan 2017 Results of subgroup analysis presented at the 2017 Gastrointestinal Cancers Symposium.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History